Evolution of Intracardiac Electrograms Recorded by Left Bundle Branch Pacing Lead in Patients With ICD or CRT-D
Launched by MEDTRONIC CARDIAC RHYTHM AND HEART FAILURE · Dec 17, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how a specific type of heart lead, called the Left Bundle Branch Pacing (LBBP) lead, records electrical signals in the heart during daily activities. The study focuses on patients who have received an implantable cardioverter-defibrillator (ICD) or a cardiac resynchronization therapy defibrillator (CRT-D) to prevent dangerous heart rhythms like ventricular tachycardia (VT) and ventricular fibrillation. The main question is whether the LBBP lead can accurately and consistently detect these heart events during different activities, such as resting and walking, over a period of six months.
To participate in this study, individuals should be 18 years or older and must have recently received an ICD or CRT-D with the LBBP lead. Participants will have their heart signals recorded using a small device that they can wear at home. The study is not yet recruiting, so there will be more information available soon for those interested in joining. It's important to know that patients who are pregnant or those who have recently had their heart device replaced or upgraded will not be eligible for this study. Your involvement could help improve heart monitoring for many patients in the future!
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients aged \>=18 yrs.
- • Patients indicated for ICD or CRT-D (primary or secondary prevention)
- • Patients who recently (\<=30 days) received ICD/CRT-D implantation with LBBP
- • Patients' EGM can be digitally recorded
- • Patients are willing to participate in the study and provide signed informed consent
- Exclusion Criteria:
- • Patients received CIED upgrade or replacement with old pacing leads
- • Patients are pregnant
- • Patients participate in another study that will confound this study
About Medtronic Cardiac Rhythm And Heart Failure
Medtronic Cardiac Rhythm and Heart Failure is a leading division of Medtronic, dedicated to advancing innovative therapies for patients with cardiac rhythm disorders and heart failure. With a commitment to improving patient outcomes, this division focuses on developing cutting-edge medical devices and solutions that enhance the management of arrhythmias and heart failure. Leveraging extensive research and clinical expertise, Medtronic Cardiac Rhythm and Heart Failure aims to transform patient care through evidence-based approaches and a robust pipeline of groundbreaking technologies. Their work not only addresses immediate clinical challenges but also contributes to the long-term health and well-being of individuals with complex cardiac conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Wenzhou, Zhejiang, China
Shanghai, , China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported